Filter by category:
Benefits of Diabetes Agents: Beyond Blood Glucose
Available:
SEPTEMBER 10
Jennifer B. Green, MD
Duke University, Durham, North Carolina, USA
Jennifer B. Green, MD, is a Professor of Medicine in Endocrinology, Metabolism, and Nutrition at Duke University and a faculty member of the Duke Clinical Research Institute. She received her doctorate from University of Virginia and completed her residency at the University of North Carolina at Chapel Hill. Dr. Green served as chief of the Endocrinology section at the Durham VA Medical Center from 2003-2017. Her clinical and research interests focus on strategies to predict, prevent, and treat diabetes mellitus and its complications.
Disclosures:
Research Support: Boehringer Ingelheim; NIDDK; Sanofi/Lexicon
Consultant: AstraZeneca; Boehringer Ingelheim/Lilly Alliance; Novo Nordisk
Learning Objectives:
- Describe the efficacy and safety of SGLT-2 inhibitor therapy in patients with renal and cardiovascular disease, and heart failure
- Discuss the evidence to support GLP-1 receptor agonist therapy in patients with cardiovascular and renal disease
- Apply the evidence for use of GLP-1 receptor agonist therapy in patients with obesity and non-alcoholic fatty liver disease.
Congenital Adrenal Hyperplasia: Management and Transition to Adulthood
Available:
SEPTEMBER 10
Richard Auchus, MD, PhD
University of Michigan, Ann Arbor, Michigan, USA
Richard J. Auchus, MD, PhD, is a Professor of Internal Medicine, Division of Metabolism, Endocrinology & Diabetes (MEND) and director of the MEND Fellowship Program. He received his medical degree and PhD in pharmacology from Washington University in St. Louis and completed a residency at the University of Iowa and an endocrinology fellowship at UTHSC-San Antonio/Wilford Hall Medical Center. Dr. Auchus is a steroid biologist with expertise both in basic science and clinical/translational science. His work has included translational research into molecular and genetic mechanisms of human hypertension, improved diagnostic studies and management in primary aldosteronism and Cushing syndromes, modifier genes in 21-hydroxylase deficiency, cardiovascular disease in polycystic ovary syndrome, and the endocrinology of traumatic brain injury.
Disclosures:
Consultant: Adrenas Therapeutics; Corcept Therapeutics; Janssen Pharmaceuticals; Novartis Pharmaceuticals; Quest Diagnostics; Strongbridge Biopharma
Contracted Research: Corcept Therapeutics; Neurocrine Biosciences; Novartis Pharmaceuticals; Spruce Biosciences
Learning Objectives:
- Explain the main differences and goals of various types of CAH management for children and adults
- Recognize the possible adverse consequences of overtreatment and undertreatment with currently available glucocorticoid preparations and regiments and possible future options
- Select optimal therapy and monitoring of patients desiring fertility in setting of CAH.
Cushing Syndrome: Tips and Pitfalls in Diagnosis and Management
Available:
SEPTEMBER 10
James W. Findling, MD
Medical College of Wisconsin, Wauwatosa, Wisconsin, USA
James W. Findling, MD, is a Clinical Professor of Medicine and Director of the Community Endocrinology Center and Clinics at the Medical College of Wisconsin. He is a graduate of the University of Notre Dame and Northwestern University Medical School. He completed his internal medicine training at the Medical College of Wisconsin and his post-doctoral fellowship in Endocrinology and Metabolism at the University of California-San Francisco. He started his endocrinology practice at St. Luke’s Medical Center in Milwaukee in 1982 and he started the Endocrine-Diabetes Center at St. Luke’s in 1987. Dr. Findling has over 100 publications and book chapters and is considered an international expert on clinical disorders of pituitary and adrenal function. He discovered the importance of inferior petrosal sinus sampling for the differential diagnosis of Cushing syndrome in the early 1980s and introduced late-night salivary cortisol as a simple screening test for Cushing syndrome in the 1990s.
Disclosures:
Investigator/Consultant: Corcept Therapeutics; Novartis
Learning Objectives:
- Outline the steps for evaluation and troubleshooting in patients with mild Cushing Syndrome vs Pseudo-Cushing Syndrome and discuss tips for cyclical disease evaluation
- Describe the evaluation and management of imaging negative or equivocal imaging results in patients with ACTH dependent Cushing Syndrome
- Identify the pros and cons of venous thromboembolism prophylaxis in patients with Cushing Syndrome.
Does When You Eat Matter for Weight Management?
Available:
SEPTEMBER 10
Krista Varady, PhD
University of Illinois, Chicago, Chicago, Illinois, USA
Krista Varady, PhD, is a Professor of Nutrition at the University of Illinois, Chicago. Her research focuses on the efficacy of intermittent fasting for weight loss, weight maintenance, and cardio-protection in obese adults. Her work is funded by the NIH, American Heart Association, International Life Sciences Institute, and the University of Illinois. She has published over 70 publications on this topic and is also the author of a book for the general public, the "Every Other Day Diet."
Disclosures:
Research Funding: American Heart Association; International Life Sciences Institute; National Institutes of Health (NIDDK R01DK110783, NHLBI, R01HL148661); Nestle Health Sciences
Conflict of Interest: Received author fees from Hachette for “Every Other Day Diet”
Learning Objectives:
- Explain the impact of circadian rhythms and their disruption on body weight regulation
- Define time restricted eating and describe the impact of time restricted eating on weight management
- Discuss the different forms of intermittent fasting and their effects on weight and metabolism.
Drug Effects on Thyroid Function
Available:
SEPTEMBER 10
James V. Hennessey, MD
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
James V. Hennessey, MD, is an Associate Professor of Medicine at Harvard Medical School and Director of Clinical Endocrinology at Beth Israel Deaconess Medical Center. He received his degree from the University of Graz in Austria and completed his residency at the Hospital of Central Connecticut. His clinical interests include thyroid, pituitary, and adrenal disorders.
Disclosures:
No relevant financial relationships.
Learning Objectives:
- Identify drugs that interfere with thyroid hormone therapy
- Discuss data regarding drugs that interfere with thyroid function laboratory tests
- Summarize current medical knowledge regarding drugs that interfere with endogenous thyroid function.
Helping Our Patients Change Behavior Using the Science of Habit Formation
Available:
SEPTEMBER 10
Robert F. Kushner, MD
Northwestern University, Evanston, Illinois, USA
Robert F. Kushner, MD, is a Professor of Medicine and Medical Education at the Feinburg School of Medicine at Northwestern University and Medical Director of the Wellness Institute at Northwestern Memorial Hospital in Chicago. He received his doctorate from the University of Illinois at Chicago and completed his residency at the McGaw Medical Center at Northwestern Memorial Hospital. Dr. Kushner has authored over 200 original articles, books, and book chapters covering on medical nutrition and obesity.
Disclosures:
Advisory Board: Novo Nordisk; WW (formally Weight Watchers)
Research Support: Novo Nordisk
Learning Objectives:
- Define the guiding principles and theories of behavior change and habit formation
- Describe the key components of cognitive behavioral treatment and motivational interviewing
- Discuss practical approaches to support behavior change in the office setting.
Highlights of the Management of Transwomen from Adolescence Through Early Adulthood
Available:
SEPTEMBER 10
Ximena Lopez, MD
UT Southwestern Medical Center, Dallas, Texas, USA
Ximena Lopez, MD, did her residency in Pediatrics at the University of Illinois at Chicago, IL, and her fellowship in Pediatric Endocrinology at Massachusetts General Hospital/Harvard Medical School, Boston, MA. She is currently the Medical Director for the GENder, Education and Care Interdisciplinary Support (GENECIS) program, which provides mental health and endocrine care for gender non-conforming children and adolescents. Dr. Lopez is also currently co-chair of the Transgender Health Special Interest Group of the Pediatric Endocrine Society.
Disclosures:
No relevant financial relationships.
Learning Objectives:
- Summarize the rationale and the benefits of risks of hormone-congruent therapy initiated early in puberty for transwomen
- Identify, initiate and manage safe and effective hormone-congruent regimens for transwomen
- Describe approaches on the preservation of fertility and long term optimization of cardiovascular and bone health.
Hypercalcemia: Common Causes, Rare Causes, and Management
Available:
SEPTEMBER 10
Thomas J. Weber, MD
Duke University Medical Center, Durham, North Carolina, USA
Thomas J. Weber, MD, is an Associate Professor of Medicine at Duke University Medical Center, where he is Medical Director of the Duke Clinical Bone Laboratory, and a Clinical Investigator in the Clinical Research Training Program of the Duke University School of Medicine. He is also a permanent member of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA, and a member of the Peer Review Committee for the Endocrine Society Self-Assessment Program (ESAP). Dr. Weber has also authored the chapters on “Osteoporosis” and “Approach to the Patient with Metabolic Bone Disease” in the 25th and 26th editions of Cecil’s Textbook of Medicine. Dr. Weber attended the University of Chicago-Pritzker medical school, and thereafter completed his internship and residency training in Internal Medicine at Yale-New Haven Hospital and a research fellowship in Endocrinology at Duke University Medical Center. His research focuses on metabolic bone disease more broadly, including the hypophosphatemic, osteomalacic disorders X-linked hypophosphatemic rickets (XLH) and tumor-induced osteomalacia, as well as clinical and translational studies of osteoporosis and primary hyperparathyroidism.
Disclosures:
Editorial Consultant: Elsevier; MedIQ
Consultant/Travel Support: Pharmacosmos
Research Support/Consultant/Travel Support: Ultragenyx
The Endocrine Society - Member, Endocrine Self-Assessment Program Faculty Peer Review Committee;
Food and Drug Administration - Permanent member, Endocrine and Metabolic Drug Advisory Committee (EMDAC)
Learning Objectives:
- Discuss the etiology of hypercalcemic disorders, a common referral question for Endocrinologists
- Identify flags that indicate an unusual cause and when further testing is indicated
- Utilize medications and surgical referrals effectively for hypercalcemia.
Hypertriglyceridemia and Cardiovascular Disease: To Treat or Not to Treat?
Available:
SEPTEMBER 10
Savitha Subramanian, MD
University of Washington, Seattle, Washington, USA
Savitha Subramanian, MD, is an Associate Professor of Medicine and Metabolism, Endocrinology and Nutrition at the University of Washington Endocrine and physician at the Diabetes Care Center at University of Washington Medical Center-Roosevelt. She received her degree from Stanley Medical College in India and completed her residency at the University of Illinois College of Medicine.
Disclosures:
No relevant financial relationships.
Learning Objectives:
- Define Hypertriglyceridemia and explain evidence for the role of triglyceride rich lipoproteins in the development of atherosclerosis
- Describe efficacy and safety in CVD outcome trials of triglyceride lowering drugs, including omega-3 fatty acids
- Identify which patients might benefit from the addition of omega-3 fatty acids or fibrates to statin therapy
- Discuss benefits and risks of omega-3 fatty acids in patients with type 2 diabetes.
Insulin Therapy: Analogues, Concentrated Insulins, and Inhaled Insulins
Available:
SEPTEMBER 10
M. Sue Kirkman, MD
University of North Carolina, Chapel Hill, North Carolina, USA
M. Sue Kirkman, MD, is the medical director of the UNC Diabetes Care Center’s Clinical Trials Unit, which consists of five investigators, five study coordinators, and three research assistants conducting 15-20 trials in type 1 and type 2 diabetes and in obesity. Dr. Kirkman is site principal investigator of several clinical trials including the NIDDK-funded GRADE study, for which she also serves as co-chair of the Outcomes Committee. She is also co-PI of a CDC-funded grant to better distinguish between type 1 and type 2 diabetes in adults using EHR and survey data. In addition to her clinical practice and research work, Dr. Kirkman is currently chair of the National Diabetes Education Program (NDEP), a joint initiative of NIDDK and the CDC.
Disclosures:
Research Investigator: Bayer; Novo Nordisk
Learning Objectives:
- Summarize the pharmacokinetic and pharmacodynamic differences among the available insulins
- Describe an approach to individualizing selection of insulin analogue therapy using cases
- Evaluate the need for use of concentrated insulin therapy using cases.
Management of Hypoparathyroidism
Available:
SEPTEMBER 10
Dolores M. Shoback, MD
University of California, San Francisco School of Medicine, San Francisco, California, USA
Dolores M. Shoback, MD, is Professor of Medicine and Associate Program Director of the Fellowship Program in Diabetes, Endocrinology and Metabolism at the University of California, San Francisco School of Medicine. She attended the University of Pennsylvania and obtained her MD from Johns Hopkins University School of Medicine. She completed Internal Medicine residency at Johns Hopkins Hospital and her fellowship in Endocrinology and Hypertension at the Brigham and Women’s Hospital/Harvard Medical School, where she developed career-long interests in endocrine hypertension, metabolic bone disease and parathyroid disorders. Dr. Shoback is active in basic and clinical research involving calcium-sensing receptors and parathyroid disorders.
Disclosures:
Investigator: NPS (Shire, Takeda)- sponsored clinical trial REPLACE on use of PTH (1-84) in adults with hypoparathyroidism
Consultant: Ascendis Pharmaceuticals; Bridge Bio; Shire
Learning Objectives:
- Identify patients with hypoparathyroidism and understand the etiologies
- Select patients who may be appropriate candidates for newer therapies
- Recognize when genetic testing for hypocalcemic disorders is indicated.
Medical Treatment of Cushing Disease
Available:
SEPTEMBER 10
Eliza B. Geer, MD
Memorial Sloan Kettering Cancer Center, New York, New York, USA
Eliza B. Geer, MD, joined the faculty at The Mount Sinai Medical Center in July, 2006 with an appointment in the Division of Endocrinology and a secondary appointment in the Department of Neurosurgery. After graduating from Columbia University, she attended Mount Sinai School of Medicine, graduating with Distinction in Research. She completed her Internship and Residency in Internal Medicine at Columbia Presbyterian Medical Center, where she became involved in neuroendocrine research, conducting studies on the hypothalamic-pituitary-adrenal axis and acromegaly. After completing her residency, she conducted a year of clinical research at Columbia's Obesity Research Center, funded by a NIH T32 grant, where she focused on body composition and appetite in acromegaly. She then completed a fellowship in Endocrinology, Diabetes and Bone Disease at the Mount Sinai Medical Center, graduating in 2006.
Disclosures:
Research Investigator: Bristol-Myers Squibb; Chiasma; Corcept; Ionis; Novartis; Strongbridge
Learning Objectives:
- Differentiate between treatment options for patients with Cushing’s disease not in remission after surgery: medical therapy X bilateral adrenalectomy
- medical treatment X radiotherapy
- Evaluate indications, risks, benefits and biomarkers of available medical therapies
- Describe the new drugs in the horizon.
Osteoporosis Medication: Timing is Everything
Available:
SEPTEMBER 10
E. Michael Lewiecki, MD
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA
E. Michael Lewiecki, MD, is Director of New Mexico Clinical Research & Osteoporosis Center and Clinical Assistant Professor of Medicine at University of New Mexico Health Sciences Center. He received his doctorate from Northwestern University Medical School and completed his postgraduate medical training at University of New Mexico Health Sciences Center. Dr. Lewiecki is currently a consultant in osteoporosis and metabolic bone disease, supervisor of bone densitometry at his center and principal investigator for their osteoporosis clinical trials, and an educator with a special interest in the management of osteoporosis and metabolic bone disease. Dr. Lewiecki is past president of the International Society for Clinical Densitometry (ISCD) and a board member of the ISCD and the National Osteoporosis Foundation. He is founding president of the Osteoporosis Foundation of New Mexico and program director of its flagship activity, the annual Santa Fe Bone Symposium. He is founder and Director of Bone Health TeleECHO (Extension for Community Healthcare Outcomes), an ongoing telementoring program for healthcare professionals focusing on osteoporosis and metabolic bone diseases.
Disclosures:
Employed by New Mexico Clinical Research & Osteoporosis Center, which has received the following in the past one year: 1) Institutional Research Grant Support
Learning Objectives:
- Identify patients at very high risk for fracture and determine which medications should be used for initial therapy
- Explain the sequence of osteoporosis medication treatment to optimize increases in bone density and fracture outcomes
- Select medications based on individual patient backgrounds and medical history.
Perioperative Management of Pituitary Tumors
Available:
SEPTEMBER 10
Anat Ben-Shlomo, MD
Cedars-Sinai Medical Center, Los Angeles, California, USA
Anat Ben-Shlomo, MD, is an Assistant Professor of Medicine at Cedars-Sinai Medical Center. She received her medical degree from Sackler Faculty of Medicine in Israel and completed her residency at Assaf HaRofeh Medical Center. Her specialties are clinical and translational-basic research in pituitary and adrenal gland disorders.
Disclosures:
No relevant financial relationships.
Learning Objectives:
- Outline pre-operative evaluation of patients with pituitary adenomas (emphasis on cortisol – should all patients be tested? what is the free T4 level that is safe?)
- Outline post-operative management of patients with pituitary adenomas (emphasis on cortisol evaluation and replacement, diabetes insipidus and hyponatremia)
- Describe the management of patients with pituitary adenomas in the operating room (glucocorticoid – stress dose, presence of the pathologist for Cushing’s disease (?), neuronavigation).
Thyroid Nodules and Cancer in Pregnant Women
Available:
SEPTEMBER 10
Angela M. Leung, MD
UCLA David Geffen School of Medicine, Los Angeles, California, USA
Angela M. Leung, MD, is an Associate Professor of Medicine at the UCLA David Geffen School of Medicine and an endocrinologist at both UCLA and the VA Greater Los Angeles Healthcare System. After pursuing her undergraduate studies at Occidental College, Dr. Leung completed her internal medicine residency and endocrinology fellowship training at Boston University School of Medicine. She also studied at the Boston University School of Public Health and obtained a master's degree in epidemiology. Dr. Leung has clinical and research interests in thyroid disorders and she also sees patients regarding parathyroid and adrenal disorders. She has published widely and lectures frequently on thyroid disease, including hyperthyroidism, hypothyroidism, thyroid nodules, thyroid cancer, and thyroid disease during pregnancy.
Disclosures:
Editorial Board and Editor: American Thyroid Association
Learning Objectives:
- Evaluate considerations regarding the timing of FNA biopsy when thyroid nodules are diagnosed during gestation
- Define appropriate TSH targets and tumor surveillance strategies in pregnant patients with a history of thyroid cancer
- Explain the effect of pregnancy on thyroid tumor progression.
Transitions in Diabetes Care: Pediatrics to Adulthood
Available:
SEPTEMBER 10
Lori Laffel, MD, MPH
Joslin Diabetes Center, Boston, Massachusetts, USA
Lori Laffel, MD, MPH, is a Professor of Pediatric at Harvard Medical School and Chief of the Pediatric, Adolescence, and Young Adult Section at Joslin Diabetes Center. She received her doctorate from the University of Miami School of Medicine and completed her residency at Children’s Hospital in Boston. Her clinical interests are maintaining and improving the health of youth with diabetes through educational and interventional approaches.
Disclosures:
Consultant: Boehringer Ingelheim; ConvaTec; Dexcom; Insulet; Insulogic; Janssen; Laxmi; LifeScan; Medtronic; Novo Nordisk; Roche; Sanofi
Grant Support: ADA; Boehringer Ingelheim; Dexcom; Eli Lilly; Helmsley Charitable Trust; Insulet; JDRF; NIH; Novo Nordisk; Sanofi
Learning Objectives:
- Outline the patient-specific factors which impact diabetes control in the young adult population
- Identify a strategic approach along with practical tools to utilize in receiving young adult patients into adult endocrinology practices
- Discuss the benefits and challenges of diabetes technology in this patient population.
Update in Diabetic Neuropathy: Approach to Evaluation and Treatment
Available:
SEPTEMBER 10
Rodica Pop-Busui, MD, PhD
University of Michigan, Ann Arbor, Michigan, USA
Rodica Pop-Busui, MD, PhD, is a prominent diabetologist at the University of Michigan in Ann Arbor, and a nationally and internationally recognized leader in the field of diabetes as a result of her extensive clinical, research, teaching, and service activities. Dr. Pop-Busui is the site Principal Investigator and member of the Steering Committee of the newly funded NIDDK trial "PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in Type 1 Diabetes" and site Principal Investigator in the NIDDK-funded trial "Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE)." Dr. Pop-Busui has received awards from the Fulbright Foundation, the American Diabetes Association, and the University of Michigan.
Disclosures:
Research: AstraZeneca- Investigator Initiated Trial to UM
Consultant: Averitas; Bayer; Boehringer Ingelheim
Member of the Steering Committee of SOUL CVOT Trial: Novo Nordisk
Learning Objectives:
- Summarize the spectrum of diabetes-associated neuropathies using a case-based approach
- Propose a guided approach to the use of screening and diagnostic modalities
- Describe the latest evidence-based treatment recommendations for symptoms related to diabetic neuropathy using a case-based approach.
Update on Acromegaly: Treatment Based on the New Guidelines
Available:
SEPTEMBER 10
Shlomo Melmed, MB ChB
Cedars-Sinai Medical Center, Los Angeles, California, USA
Shlomo Melmed, MB ChB, is Executive Vice-President and Dean at Cedars-Sinai Medical Center and holds the Helene A. and Philip E. Hixon Chair in Investigative Medicine. He has been a recipient of the Endocrinology Medal of the Royal Society of Medicine, the Endocrine Society Clinical Investigator and Outstanding Scholarly Physician Awards, the Society of Endocrinology Transatlantic Medal, the Fondation IPSEN Endocrine Regulations Prize, and the Pituitary Society's Lifetime Achievement Award. Dr. Melmed’s research is devoted to molecular pathogenesis and treatment of pituitary tumors and growth factor regulation of anterior pituitary function. He edits The Pituitary and co-edits Williams Textbook of Endocrinology; he co-authors Harrison's Textbook of Medicine pituitary section, is editor-in-chief of Pituitary, and is on the editorial board of Journal of Clinical Investigation and past Editor-in-Chief of Endocrinology. He served on NIH Endocrinology Study Section, was president and founding member of the Pituitary Society, member of Endocrine Society Council and President of International Society of Endocrinology. He is Program Chair of the International Congress of Endocrinology, and a Board Member of the California Institute of Regenerative Medicine (CIRM).
Disclosures:
Scientific Consultant: Chiasma; Crinetics; Ionis
Research Grant Support: Ipsen; Pfizer
Learning Objectives:
- Translate relevant data published from the new guidelines
- Discuss potential benefits and limitations of biomarkers in drug choice
- Describe the new drugs in the horizon (with special emphasis on the recently FDA approved oral octreotide – which patient will benefit from this drug?).
Update on Klinefelter Syndrome: Diagnosis and Management
Available:
SEPTEMBER 10
Alvin M. Matsumoto, MD
University of Washington, Seattle, Washington, USA
Alvin M. Matsumoto, MD, directs, serves as an attending and sees patients in the GRECC Osteoporosis & Andrology Clinic, a multi-disciplinary subspecialty referral clinic for the evaluation and treatment of patients with osteoporosis and other metabolic bone disease and male hypogonadism. He also serves as an attending physician, sees patients, and teaches residents and medical students on the Geriatrics House Staff Service of Community Living Center/Transitional Care Unit at the VA Puget Sound Health Care System. Dr. Matsumoto directs the VA Special Fellowship Program in Advanced Geriatrics, a fellowship for research training in gerontology, geriatric medicine and geriatric psychiatry. Dr. Matsumoto’s research program examines the physiological and clinical effects and mechanisms of action of androgens and their active metabolites in young and aging men. Specifically, his multi-disciplinary and collaborative research program investigates androgen effects on body composition (fat mass, lean mass and bone mineral density), muscle mass and strength, metabolic function, prostate gland and cardiovascular disease, pituitary gonadotropin secretion, spermatogenesis, sexual function, cognitive function, mood and quality of life.
Disclosures:
Research Support: AbbVie
Royalty: UpToDate (Klinefelter Syndrome)
Co-Chair: Partnership for the Accurate Testing of Hormones (PATH)
Learning Objectives:
- Recognize the variable phenotypes of Klinefelter syndrome during male infancy, puberty and adulthood
- Identify the diagnostic evaluation of a male with Klinefelter syndrome based on the clinical presentation
- Discuss the management of hypogonadism and infertility in male with Klinefelter syndrome.
An Update on Thyroid Surgery
Available:
SEPTEMBER 10
Michael W. Yeh, MD
UCLA, Los Angeles, California, USA
Michael W. Yeh, MD, is Founder and Director of the Endocrine Surgery Program and Assistant Professor at UCLA. After pursuing his studies at Stanford University and Harvard Medical School, Dr. Yeh trained in general surgery at UC San Francisco. He then completed the prestigious T.S. Reeve International Fellowship in endocrine surgery at the Royal North Shore Hospital in Sydney, Australia. Dr. Yeh is an expert in minimally invasive parathyroid surgery, thyroid cancer, and adrenal tumors, including pheochromocytoma and adrenocortical carcinoma. He has published more than 100 scholarly articles and book chapters on these topics.
Disclosures:
No relevant financial relationships.
Learning Objectives:
- Describe the harms and benefits related to thyroid surgery decision making strategies
- Identify which patients with thyroid cancer are appropriate candidates for lobectomy vs. total thyroidectomy
- Recognize strategies recommended by current guidelines.
What Endocrinologists Should Know About Female Hormonal Contraceptives
Available:
SEPTEMBER 10
Subbulaxmi Trikudanathan, MD, MMSc
University of Washington, Seattle, Washington, USA
Subbulaxmi Trikudanathan, MD, MMSc, is a Clinical Associate Professor of Medicine at the University of Washington and is the Medical Director of the UW Diabetes Institute. She obtained her medical degree from Madras Medical College in India and her MMSc from Harvard. She completed multiple residencies and fellowships in both the USA and the UK, including a final endocrinology fellowship at Brigham and Women’s Hospital in Boston, MA.
Disclosures:
No relevant financial relationships.
Learning Objectives:
- Identify the advantages and disadvantages of various hormonal contraceptive formulations in women of reproductive age who have common endocrinopathies including diabetes mellitus, dyslipidemia, hypothyroidism or polycystic ovary syndrome
- Discuss how to initiate hormone contraceptives in women of reproductive age who have hirsutism and a history of risk factors for cardiovascular and thromboembolic disease
- Explain how to initiate and manage hormonal contraceptive therapy in perimenopausal women with severe hot flashes, low bone mineral density or personal preference for such therapy.